Activity Overview
The management of small cell lung cancer has been transformed with the introduction of novel immunotherapeutic strategies into the standard of care. In this online activity, 2 expert faculty in the management of small cell lung cancer discuss the emergence and evolution of DLL3-directed therapies, including concepts like data supporting the use of these agents, ongoing clinical trials, and management of key adverse events.
Target Audience
This educational activity is directed toward oncologists, pathologists, and other physicians interested in the treatment of SCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the mechanism of action of DLL3-targeting bispecific and trispecific T-cell engagers to treat SCLC
- Discuss how recent trial evidence of DLL3-targeting therapies may inform future treatment selections for patients with SCLC
- Discuss strategies to mitigate risk, identify, and manage toxicities associated with DLL3-targeted therapies in patients with SCLC